Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials

Affiliation auteurs!!!! Error affiliation !!!!
TitreVery accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials
Type de publicationJournal Article
Year of Publication2017
AuteursTao Y, Auperin A, Graff P, Lapeyre M, Gregoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J
JournalORAL ONCOLOGY
Volume71
Pagination61-66
Date PublishedAUG
Type of ArticleArticle
ISSN1368-8375
Mots-clésAccelerated radiotherapy, Concurrent chemoradiotherapy, Distant metastasis, Head and Neck cancer, N3, Oropharyngeal cancer
Résumé

{Objective: To analyze the outcome of N3 patients treated with very accelerated radiotherapy (VART) or different schedules of concurrent chemoradiotherapy (CRT) within two phase III trials. Patients and methods: Data of 179 patients with N3 HNSCC from two GORTEC randomized trials (96-01 and 99-02) were pooled. Patients received either VART: 64.8 Gy/3.5 weeks or one of the 3 following CRT regimens: Conventional CRT: 70 Gy/7 weeks + 3 cycles carboplatin-5FU; Moderately accelerated CRT: 70 Gy/6 weeks + 2 cycles carboplatin-5FU; Strongly intensified CRT: 64 Gy/5 weeks + cisplatin (days 2, 16, 30) and 5 FU (days 1-5, 29-33) followed by 2 cycles adjuvant cisplatin-5FU. Results: Median follow-up was 13.3 and 5.2 years for GORTEC 96-01 and GORTEC 99-02, respectively. Five-year overall survival (OS) was 13.8%. No significant difference was observed between CRT versus VART in terms of OS (hazard ratio [HR]: 0.93
DOI10.1016/j.oraloncology.2017.06.002